<DOC>
	<DOCNO>NCT02190318</DOCNO>
	<brief_summary>Aldosterone blockade useful preserve residual renal function patient PD.The long term efficacy dual blockade RAAS good monotherapy .</brief_summary>
	<brief_title>Residual Renal Function Preservation Peritoneal Dialysis Patients</brief_title>
	<detailed_description>Residual renal function proven contribute improved survival quality life dialysis patient . It recognize important factor prognosis PD.The RAAS system involve development renal disease . Angiotensin II aldosterone vital process . The beneficial effect angiotensin-converting enzyme inhibitor angiotensin receptor blocker residual renal function demonstrate peritoneal dialysis patient . Unfortunately , neither ACE inhibition angiotensin receptor blocker fully supprsses aldosterone production . Now much focus place aldosterone antagonist .</detailed_description>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Patients PD continuously one month , urine volume＞600 ml/d , residual renal function＞2ml/min/1.73m2 , blood pressure＞120/70mmHg , serum potassium levels＜5.5mmol/l , stable clinical condition . Patients infectious systemic disease , peritonitis precede 1 month , take ACEI/ARBs 3 precede month , spirolactone 2 preceding week , intolerance ACEI/ARBs , CHF , MI , malignant hypertension stroke within precede 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>peritoneal dialysis；</keyword>
	<keyword>residual renal function；</keyword>
	<keyword>RAAS</keyword>
</DOC>